Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.…
Satellos Bioscience's Phase 2 Data Readout Could Drive Significant Upside, Oppenheimer Says
Satellos Bioscience (NASDAQ: MSLE) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 18 employees.
The shares were at 5.680 USD on 20 November 2026, down 5.3% over 52 weeks. Its 52-week range is 5.304 USD to 13.39 USD: the price is 57.6% below the high and 7.1% above the low.
Its market capitalisation is 120.51M USD.
Satellos Bioscience reports return on equity of -89.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 61.84M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 March 2027.